𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma

✍ Scribed by Chong-Kin LIAM; Yong-Kek PANG; Chai-Hooi LEOW

Book ID
108964449
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
132 KB
Volume
11
Category
Article
ISSN
1323-7799

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cost-effectiveness of epidermal growth f
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven

Epidermal growth factor receptor mutatio
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
✍ Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Me πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 161 KB πŸ‘ 2 views

## Abstract Recently, mutations in the __epidermal growth factor receptor__ (__EGFR__) gene in nonsmall cell lung cancer (NSCLC) patients were reported to correlate with gefitinib response. Less than 30% of NSCLC patients are surgically resectable; however, molecular analysis has to rely on nonsurg